Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.07 and traded as low as $4.26. Titan Pharmaceuticals shares last traded at $4.30, with a volume of 12,361 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on Titan Pharmaceuticals in a research report on Thursday. They set a “sell” rating on the stock.
Read Our Latest Stock Report on Titan Pharmaceuticals
Titan Pharmaceuticals Price Performance
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- How to Plot Fibonacci Price Inflection Levels
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Growth Stocks and Investing in Them
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Pros And Cons Of Monthly Dividend Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.